scholarly journals Doença Oncológica: Perfil Epidemiológico em Unidade de Referência na Amazônia

2020 ◽  
Vol 11 (3) ◽  
Author(s):  
Mayrla Santana Picanço ◽  
Lucyelle Gleyce Ferreira Pádua ◽  
Francineide Pereira da Silva Pena ◽  
Maria Virginia Filgueiras de Assis Mello ◽  
Walter De Souza Tavares
Keyword(s):  
Prostate Cancer ◽  
Cáncer De Mama ◽  
Male Population ◽  
Cross Sectional ◽  
Female Population ◽  
Primary Schooling ◽  
Cáncer De Próstata ◽  
Epidemiological Profile ◽  
National Profile

Objetivo: Identificar o perfil epidemiológico, sociodemográfico, clínico e os cuidados de enfermagem no seguimento de pessoas com doença oncológica no estado do Amapá. Metodologia: Estudo transversal, descritivo, documental. Os dados foram coletados dos prontuários, por roteiro sistematizado, na amostra de 320 prontuários, no período de 2014 a 2018. Resultados: Predomínio do sexo feminino (55%), faixa etária entre 60 – 69 anos (21%), escolaridade ensino fundamental incompleto (40%). O câncer de colo uterino (33%) foi predominante no sexo feminino, e o de próstata (30%) no sexo masculino. Conclusão: O perfil identificado no Amapá para a população masculina foi o câncer de próstata, que se semelhou ao perfil nacional, já para a população feminina, fugiu do perfil nacional, onde o câncer de mama responde pelo topo do ranking, enquanto no Amapá é o de colo uterino.Descritores: Neoplasias; Epidemiologia; Enfermagem.ONCOLOGICAL DISEASE: EPIDEMIOLOGICAL PROFILE IN A REFERENCE UNIT IN THE AMAZONObjective: To identify the epidemiological, sociodemographic, clinical profile and the nursing care in the follow up of peoples with oncological disease in the state of Amapá. Methodology: cross-sectional, descriptive, documentary study. The data were collected from the medical records by a systematized script, with a sample of 320 records of interventions that occurred in the period from 2014 to 2018. Results: The predominance was female (55%), aged over 60 (21% ), incomplete primary schooling (40%). Cervical cancer was the most identified (33%) in the female sex, and the prostate cancer (30%) in the male sex. Conclusion: The profile identified in Amapá for the male population admits prostate cancer, a characteristic similar to the national profile, already for the female population, runs away from the national profile, where breast cancer is at the top of the ranking, while in Amapá it is the uterine cervix.Descriptors: Neoplasms; Epidemiology; Nursing.ENFERMEDAD ONCOLÓGICA: PERFIL EPIDEMIOLÓGICO EN UNA UNIDAD DE REFERENCIA EN LA AMAZONÍAObjetivo: Identificar el perfil epidemiológico, sociodemográfico, clínico y la atención de enfermería en el seguimiento de personas con enfermedad oncológica en el estado de Amapá. Metodología: Estudio transversal, descriptivo, documental. Los datos fueron recolectados de los prontuarios, por itinerario sistematizado, teniendo una muestra de 320 prontuarios, de intervenciones ocurridas en el período de 2014 a 2018. Resultados: Ocurrió el predominio del sexo femenino (55%), del grupo de edad superior a los 60 (21%) de la escolaridad escolar incompleta (40%). El cáncer de cuello uterino fue el más identificado (33%) en el sexo femenino, y el de próstata (30%) en el sexo masculino. Conclusión: El perfil identificado en Amapá para la población masculina admite el cáncer de próstata, característica similar al perfil nacional, ya para la población femenina, huye del perfil nacional, donde el cáncer de mama es el que está en la cima del ranking, en el Amapá es el de cuello uterino. Descriptores: Neoplasias; Epidemiología; Enfermería.

scholarly journals Câncer de mama e próstata no Brasil: análise epidemiológica / Breast cancer and prostate in Brazil: epidemiological analysis

2021 ◽  
Vol 66 (1u) ◽  
pp. 1
Author(s):  
Lindcy Maticolli Cesar ◽  
Lucas Boa Sorte Faccin ◽  
Maiana Gueretta Martinez ◽  
Angélica Augusta Grigoli Dominato
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Mortality Rate ◽  
Female Breast Cancer ◽  
Cáncer De Mama ◽  
Cáncer De Próstata ◽  
Age Related ◽  
Incidence And Mortality ◽  
Breast And Prostate Cancer ◽  
Epidemiological Profile

Introdução: O câncer está entre as principais doenças causadoras de morbimortalidade mundial relacionada com a idade, sendo mais comum entre pacientes com menos de 70 anos, e associado ao sexo com o câncer de mama feminino e de próstata para os homens. Objetivo: Traçar o perfil epidemiológicodos brasileiros acometidos pelo câncer próstata e de mama nas mulheres, comparar suas incidências e taxas de mortalidade nas macrorregiões do país. Metodologia: O estudo é descritivo do tipo ecológico com abordagem quantitativa dos dados da taxa de mortalidade, obtidos sobre o câncer de mama feminino e de próstata nas macrorregiões brasileiras, entre os anos de 2009 a 2018. Resultados: Os dados levantados mostraram que o total de óbitos entre mulheres nos anos do estudo foi de 5.315.155, sendo que 2,72% a foi causado pelo câncer de mama. Enquanto que, o número de óbitos entre os homens foi de 6.911.531, sendo 2,02% atribuídos ao câncer de próstata. Conclusão: Observou-se aumento da mortalidade de pacientes com câncer de mamae próstata no país ao longo do tempo do estudo, assim como aumento da taxa de mortalidade para ambos. Palavras chave: Câncer de mama, Câncer de próstata,Epidemiologia, Mortalidade, Incidência ABSTRACTIntroduction: Cancer is among the main diseases causing age-related morbidity and mortality worldwide, being more common among patients under 70 years, and associated with gender with breast cancer for women and prostatecancer for men. Objective: To trace the epidemiological profile of Brazilians affected by prostate and breast cancer in women, compare their incidence and mortality rates in the macro-regions of the country. Methodology: The study is descriptive of ecological type with quantitative approach of mortality rate data, obtained on female breast cancer and prostate cancer in Brazilian macro-regions, between the years 2009 to 2018. Results: The data surveyed showed that the total number of deaths among women in the years of the study was 5,315,155, 2.72% a was caused by breast cancer. Whereas, the number of deaths among men was 6,911,531, with 2.02% attributed to prostate cancer. Conclusion: We observed an increase in mortality of patients with breast and prostate cancer in the country over the time of the study, as well as an increase in the mortality rate for both.Keywords: Breast cancer, Prostate cancer, Epidemiology, Mortality, Incidence

scholarly journals PERFIL EPIDEMIOLÓGICO DAS PACIENTES COM CÂNCER DE MAMA SUBMETIDAS A QUIMIOTERAPIA NEOADJUVANTE EM UM HOSPITAL DE SÃO LUIS-MA

2018 ◽  
Vol 5 (2) ◽  
pp. 21-24
Author(s):  
FERNANDO HENRIQUE RIBEIRO DO COUTO CORREA
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Treatment ◽  
Epidemiological Data ◽  
Cross Sectional Study ◽  
Cáncer De Mama ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Epidemiological Profile ◽  
Surgical Treatments

RESUMO Introdução: Anualmente são diagnosticados aproximadamente um milhão de novos casos de câncer, existindo uma prevalência de 4,4 milhões de mulheres que padecem dessa enfermidade. A quimioterapia neoadjuvante, é definida como qualquer tratamento quimioterápico prescrito antes do tratamento cirúrgico, com base nos resultados obtidos, passou-se a indicar o tratamento neoadjuvante em pacientes com tumores operáveis, permitindo a utilização de tratamentos cirúrgicos menos invasivos e  mais eficientes. Metodologia: Estudo retrospectivo, de corte transversal  para avaliar o perfil clínico-epidemiológico de pacientes com câncer de mama sob acompanhamento do Serviço de Mastologia do Hospital do Câncer Aldenora Belo (HCAB) na cidade de São Luis-MA  com uma amostragem de 56 pacientes durante o período de janeiro de 2015 a dezembro de 2015. RESULTADOS: Os resultados referem-se a 56 pacientes com dados clínico-epidemiológicos. Conclusão:  Os resultados encontrados demonstram a evolução no tratamento do câncer de mama avançado, o que é uma realidade em nossa região, devido a falta de programas de acesso ao rastreamento, principalmente no interior do Estado, o que permitiria diagnósticos precoces e tratamentos mais eficazes e menos lesivos a paciente.   Palavras-chave: Oncologia. Mama. Neoplasias. ABSTRACT Introduction: Approximately one million new cases of cancer are diagnosed annually, with a prevalence of 4.4 million women suffering from this disease. Neoadjuvant chemotherapy is defined as any chemotherapy treatment prescribed before the surgical treatment, based on the results obtained, it was indicated the neoadjuvant treatment in patients with operable tumors, allowing the use of less invasive and more efficient surgical treatments. Methodology: Retrospective, cross-sectional study to evaluate the clinical-epidemiological profile of breast cancer patients under follow-up of the Mastology Service of the Aldenora Belo Cancer Hospital (HCAB) in the city of São Luis-MA with a sample of 56 patients during the period from January 2015 to December 2015. RESULTS: The results refer to 56 patients with clinical-epidemiological data. Conclusion: The results show the evolution in the treatment of advanced breast cancer, which is a reality in our region, due to the lack of access programs to the tracing, mainly in the interior of the State, which would allow early diagnosis and more effective treatments and less harmful to the patient. Keywords: Oncology. Mama. Neoplasms.

scholarly journals Early detection of prostate cancer local recurrence by urinary prostate-specific antigen

2013 ◽  
Vol 3 (3) ◽  
pp. 213 ◽  
Author(s):  
Stéphane Bolduc ◽  
Brant A. Inman ◽  
Louis Lacombe ◽  
Yves Fradet ◽  
Roland R. Tremblay
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Laboratory Assessment ◽  
Cross Sectional ◽  
Prostatectomie Radicale ◽  
Psa Recurrence ◽  
Patients Atteints De Cancer

Purpose: We assessed the role of urinary prostate-specific antigen(uPSA) in the follow-up of prostate cancer after retropubic radicalprostatectomy (RRP) for the early detection of local recurrences.Methods: We recruited 50 patients previously treated for prostatecancer with RRP and who had not experienced a prostatespecificantigen (PSA) recurrence within their first postoperativeyear into a cross-sectional laboratory assessment and prospective6-year longitudinal follow-up study. We defined biochemicalfailure as a serum PSA (sPSA) of 0.3 μg/L or greater. Patientsprovided blood samples and a 50-mL sample of first-voided urine.We performed Wilcoxon rank-sum and Fisher exact tests for statisticalanalysis.Results: The median sPSA was 0.13 μg/L. The median uPSA was0.8 μg/L, and was not significantly different when comparingGleason scores or pathological stages. Of the 50 patients, 27 initiallyhad a nondetectable sPSA but a detectable uPSA, and11 patients experienced sPSA failure after 6 years. Six patients haddetectable sPSA and uPSA initially. Fifteen patients were negativefor both sPSA and uPSA, and 13 remained sPSA-free after 6 years.The odds ratio (OR) of having sPSA failure given a positive uPSAtest was 4.5 if sPSA was undetectable, but was reduced to 2.6 ifsPSA was detectable. The pooled Mantel–Haenszel OR of 4.2 suggestedthat a detectable uPSA quadrupled the risk of recurrence,independent of whether sPSA was elevated or not. The sensitivityof uPSA for detecting future sPSA recurrences was 81% andspecificity was 45%.Conclusion: Urinary PSA could contribute to an early detection oflocal recurrences of prostate cancer after a radical prostatectomy.Objectif : Nous avons évalué le rôle de l’antigène prostatiquespécifique (APS) urinaire dans le suivi du cancer de la prostateaprès prostatectomie radicale rétropubienne (PRR) pour le dépistageprécoce de récidives locales.Méthodes : Cinquante patients atteints de cancer de la prostatetraités par PRR et n’ayant présenté aucune récidive avec anomaliede l’APS dans l’année suivant l’intervention chirurgicale ontété inscrits à une étude transversale par épreuves de laboratoireavec suivi longitudinal prospectif sur 6 ans. L’échec sur le planbiochimique était défini comme un taux d’APS sérique de 0,3 μg/Lou plus. Les patients devaient fournir des échantillons de sanget un échantillon d’urine du matin de 50 mL. Les analyses statistiquesreposaient sur le test de Wilcoxon et la méthode exactede Fisher.Résultats : La valeur médiane de l’APS sérique était de 0,13 μg/L.La valeur médiane de l’APS urinaire était de 0,8 μg/L; la différenceétait non significative quand on tenait compte des scores deGleason ou des stades pathologiques. Sur les 50 patients,27 présentaient des taux d’APS sérique non décelables au début,mais des taux d’APS urinaire décelables; 11 patients ont présentéun échec quant aux taux d’APS sérique après 6 ans. Six patientsavaient des taux d’APS sérique et urinaire décelables au départ.Quinze patients n’avaient aucun taux décelable d’APS sérique ouurinaire, et aucun APS sérique n’était toujours décelable chez13 patients après 6 ans. Le rapport de risque d’un échec quantaux taux d’APS sérique après détection d’APS urinaire est de 4,5en l’absence d’un taux d’APS sérique décelable, mais diminueà 2,6 en présence d’un taux d’APS sérique décelable. Le rapportde risque cumulé de 4,21 calculé par la méthode deMantel–Haenszel porte à croire que des taux d’APS urinaire décelablesquadruplent le risque de présenter une récidive, queles taux sériques soient élevés ou non. La sensibilité du test dedépistage de l’APS urinaire pour la détection des récidives avecanomalie des taux sériques était de 81 %, et la spécificité, de 45 %.Conclusion : Le taux d’APS urinaire peut contribuer à un dépistageprécoce des récidives locales après une prostatectomie radicale.

scholarly journals Epidemiologic study of chronic osteomyelitis in Paktya and Kabul, Afghanistan

2020 ◽  
Vol 8 (9) ◽  
pp. 3183
Author(s):  
Oryakhil Walikhan ◽  
Nejrabi Bismellah
Keyword(s):  
Chronic Osteomyelitis ◽  
Epidemiologic Study ◽  
Underlying Disease ◽  
Cross Sectional Study ◽  
General Information ◽  
Regional Hospital ◽  
Male Population ◽  
Humid Climate ◽  
Cross Sectional ◽  
Female Population

Background: Osteomyelitis is an infection of the bone that can occur from direct or indirect invasion by a pathogens, both of these types can potentially progress to subacute and chronic osteomyelitis that lasts longer than 4 weeks. This disease has important characteristics such as long-term clinical course, long periods of silence, the treatment of the recurrence of serious complications of the disease is difficult financially and it takes a lot of money epidemiology of chronic osteomyelitis in the Afghanistan is largely unknown. The aim of this study was epidemiologic study of chronic osteomyelitis in adult clients of Paktya city regional hospital and Wazir Akbar Khan Hospital in Kabul city of Afghanistan.Methods: This descriptive cross-sectional study was performed in patients' with chronic osteomyelitis who referred in this two hospitals in Paktya city regional hospital and the Wazir Akbar Khan hospital in Kabul During the March 2019 to March 2020, 70 patients were identified with chronic osteomyelitis. The information required for the study, such as general information, underlying diseases of the patients collected from these two medical centers. After encoding, the necessary information was entered into the computer and analyzed.Results: According to the findings of this study the prevalence of chronic bone infections in male were 64% (n=45) in female were 36% (n=25), current findings showed 44.3% of all patient involved with tibial (n=31) chronic osteomyelitis and the most common underlying disease causing chronic osteomyelitis is the direct entry of infection as a result of trauma.Conclusions: Our study showed the chronic osteomyelitis is higher in the male population than in the female population and highest incidence of chronic osteomyelitis site was tibia result of trauma because of humid climate, poor personal and hospital environmental health status and relatively poor medical facilities in Afghanistan may contribute to higher morbidity.

scholarly journals Effects of Radiotherapy or Radical Prostatectomy on the Risk of Long-Term Heart-Specific Death in Patients With Prostate Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Yadong Guo ◽  
Xiaohui Dong ◽  
Fuhan Yang ◽  
Yang Yu ◽  
Ruiliang Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Radical Prostatectomy ◽  
Male Population ◽  
Cumulative Mortality ◽  
Specific Disease ◽  
Specific Mortality ◽  
General Male Population

Objective: The prognosis of patients with prostate cancer (PCa) has improved in recent years, but treatment-related cardiotoxicity remains unclear. This study investigated the heart-specific mortality and prognostic factors of patients with PCa after radiotherapy (RT) or radical prostatectomy (RP), and compared their long-term heart-specific mortality with that of the general male population.Materials and Methods: Data were taken from the Surveillance, Epidemiology, and End Result (SEER) database. Patients with PCa were included who underwent RT or RP from 2000 to 2012, and were followed through 2015. A cumulative mortality curve and a competitive risk regression model were applied to assess the prognostic factors of heart-specific mortality. Standardized mortality rates (SMRs) were calculated.Results: Of 389,962 men, 49.7% and 50.3% received RP and RT, respectively. The median follow-up was 8.3 years. For patients given RT, in about 9 years postdiagnosis, the cumulative mortality due to heart-specific disease exceeded that due to PCa. In patients who underwent RP, cumulative mortality from heart-specific disease or PCa was comparable. Relative to the general male population, overall, the heart-specific mortality of patients with PCa receiving RT or RP was not higher, but in patients aged 70 to 79 years, those given RT experienced slightly higher heart-specific mortality than the age-matched general population.Conclusions: Patients with PCa treated with RT or RP overall do not incur risk of heart-specific mortality higher than that of the general male population, except for patients aged 70–74 years receiving RT.

scholarly journals Outbreak investigation of acute diarrheal disease in Palitana urban, Gujarat

2017 ◽  
Vol 4 (7) ◽  
pp. 2294
Author(s):  
Bharti Koria ◽  
B. P. Boricha ◽  
Hirava Munsi ◽  
Jatin Sarvaiya
Keyword(s):  
Attack Rate ◽  
Diarrheal Disease ◽  
Age Groups ◽  
Secondary Data ◽  
Polluted Water ◽  
Health Staff ◽  
Male Population ◽  
Cross Sectional ◽  
Female Population ◽  
Adult Age

Background: Clustering of diarrhoea and vomiting cases were reported in Palitana urban on 22 December 2014. Rapid response team was sent from government medical college, Bhavnagar to control the epidemic. Methods: A cross sectional study was conducted in Palitana urban for acute diarrheal disease epidemic investigation. Secondary data obtained from health staff and analysed to have clear picture of epidemic. Necessary actions were taken to control it. Results: Total 390 cases were reported. Out of them 21-30 adult age group was more affected as compared to other age groups. Attack rate of diarrheal disease was more in male population (85.61%) as compared to female population (40.99%).Over all attack rate was 64.19%. Conclusions: It was an acute diarrheal disease outbreak due to mixing of drinking water with polluted water. 

Green tea extract to prevent colorectal adenomas in men and women: Results of the MIRACLE trial.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 1551-1551
Author(s):  
Thomas Jens Ettrich ◽  
Julia Stingl ◽  
Stefan Menzler ◽  
Helmut Messmann ◽  
Gerhard Kleber ◽  
...  
Keyword(s):  
Green Tea ◽  
Statistical Significance ◽  
Daily Intake ◽  
Multicenter Trial ◽  
Green Tea Extract ◽  
Colorectal Adenomas ◽  
Male Population ◽  
Female Population ◽  
Tea Extract

1551 Background: Prevention of colorectal adenomas (CA) can reduce colorectal cancers (CRC). Epidemiological and experimental data suggest that the green tea catechin epigallocatechingallate has an antineoplastic effect in the large bowel. MIRACLE is the largest trial so far to examine the effect of three-year daily intake of green tea extract (GTE) on the incidence of metachronous CA in a Caucasian population. Methods: Prospective, parallel group, double-blinded, placebo-controlled, randomized multicenter trial (40 German centers, recruitment 11/2011-6/2015). Patients (n = 1001, age 50-80y), polypectomy ≤ 6 months and tolerating GTE well (one-month run-in) were randomized to receive decaffeinated GTE standardized to EGCG (150 mg bid, capsules) or placebo (P) for 3 years. Primary endpoint: Incidence of metachronous CA at the 3-year follow-up colonoscopy. Secondary endpoints: Occurrence, number, localization, size, histological subtype of CA, frequency of CRC, biomarker and safety. Strata: study center, low-dose aspirin (≤100 mg/d). Results: Clinical parameters were well balanced. CA incidence at the 3-year follow-up colonoscopy was analyzed in the modified ITT set (modITT; n = 309 patients (GTE), n = 323 (placebo), timely follow up colonoscopy) and the per protocol set (PP, modITT set without major protocol violations). Incidence of CA was 55.7 % (P) and 51.1% (GTE), (modITT, adj. RR 0.905, one sided, p = 0.081), respectively 54.3 % (P) and 48.3% (GTE) (PP, adj. RR 0.883, one sided, p = 0.058). These differences did not reach statistical significance. In the preplanned exploratory analysis regarding gender incidence of CA in females was 47.9% (P) and 47.6% (GTE) in the modITT-set (adj. RR 0.989; 95%-CI: 0.753,1.299; p = 0.935), respectively 45.4% (P) and 46.9% (GTE) in the PP-set (adj. RR 1.014; 95%-CI: 0.748, 1.373; p = 0.930). In contrast, in the male population incidence of CA in the follow-up colonoscopy was 60.4% (P) and 52.9% (GTE) in the modITT-set (adj. RR 0.846; 95% CI 0.717, 0.999); p = 0.048), respectively 59.1% (P) and 49.1% (GTE) in the PP-set (RR 0.803, 95% CI: 0.666, 0.969; p = 0.022). Thus, GTE intake was associated with a significant, 12.4 relative and 7.5% absolute reduction of metachronous CA in the male modITT population. There were no differences with respect to safety between the groups. Conclusions: GTE reduced the incidence of metachronous CA. However, a significant effect was only observed in the in the male population whereas there was no effect in the female population. Clinical trial information: NCT 01360320.

scholarly journals Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment

2020 ◽  
Vol 105 (9) ◽  
pp. e3293-e3299 ◽  
Author(s):  
Iris de Nie ◽  
Christel J M de Blok ◽  
Tim M van der Sluis ◽  
Ellis Barbé ◽  
Garry L S Pigot ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cohort Study ◽  
Gender Identity ◽  
Prostate Cancer Risk ◽  
Hormone Treatment ◽  
Androgen Deprivation ◽  
Male Population ◽  
In Trans ◽  
Trans Women

Abstract Context Trans women (male sex assigned at birth, female gender identity) mostly use antiandrogens combined with estrogens and can subsequently undergo vaginoplasty including orchiectomy. Because the prostate remains in situ after this procedure, trans women are still at risk for prostate cancer. Objective To assess the incidence of prostate cancer in trans women using hormone treatment. Design In this nationwide retrospective cohort study, data of participants were linked to the Dutch national pathology database and to Statistics Netherlands to obtain data on prostate cancer diagnosis and mortality. Setting Gender identity clinic. Participants Trans women who visited our clinic between 1972 and 2016 and received hormone treatment were included. Main Outcome Measures Standardized incidence ratios (SIRs) were calculated using the number of observed prostate cancer cases in our cohort and the number of expected cases based on age-specific incidence numbers from the Netherlands Comprehensive Cancer Organization. Results The study population consisted of 2281 trans women with a median follow-up time of 14 years (interquartile range 7-24), and a total follow-up time of 37 117 years. Six prostate cancer cases were identified after a median 17 years of hormone treatment. This resulted in a lower prostate cancer risk in trans women than in Dutch reference males (SIR 0.20, 95% confidence interval 0.08-0.42). Conclusions Trans women receiving androgen deprivation therapy and estrogens have a substantially lower risk for prostate cancer than the general male population. Our results support the hypothesis that androgen deprivation has a preventive effect on the initiation and development of prostate cancer.

scholarly journals Triagem neonatal para fenilcetonúria e hiperfenilalaninemia permanente: a base de dados do IJC de 2010 a 2015 / Neonatal screening for phenylketonuria and permanent hyperphenylalaninemia: the database of IJC from 2010 to 2015

2021 ◽  
Author(s):  
Alline Coiado ◽  
Marina Sampaio ◽  
Thais Tellini ◽  
Sônia Marchezi Hadachi ◽  
Lene Garcia Barbosa
Keyword(s):  
Newborn Screening ◽  
Cross Sectional Study ◽  
First Year ◽  
Screening Methods ◽  
Sectional Study ◽  
Cross Sectional ◽  
Female Population ◽  
Reference Service ◽  
First Year Of Life

  Objetivo: A fenilcetonúria é uma das principais causas de deficiência intelectual, e possui tratamento eficaz, se realizado o diagnóstico e tratamento de forma precoce e um acompanhamento por toda vida. O objetivo deste trabalho é levantar a prevalência de recém-nascidos portadores de fenilcetonúria identificados pela triagem neonatal. Métodos: Estudo transversal no qual foi feito um levantamento de dados sobre triagem neonatal para doença fenilcetonúria realizada num Serviço de Referência de Triagem Neonatal, no período de 1 de janeiro de 2010 a 31 de dezembro de 2015. Resultados: Foi encontrado no período de 5 anos, uma prevalência aproximada de fenilcetonúria de 1: 14.700 e de hiperfenilalaninemia permanente é de 1: 54.500 nascidos vivos. Por meio dos resultados obtidos é possível demonstrar a relevância das recoletas e do seguimento no primeiro ano de vida e de amostras alteradas, assim como a gravidade da população feminina portadora de fenilcetonúria e hiperfenilalaninemia benigna, enfatizando o aumento de possíveis danos cerebrais na fase gestacional. Conclusão: A prevalência de fenilcetonúria e  hiperfenilalaninemia permanente é alta. As recoletas e o seguimento no primeiro ano de vida das amostras alteradas é de extrema importância, principalmente para a população feminina portadora de fenilcetonúria e hiperfenilalaninemia permanente, enfatizando o aumento de possíveis danos cerebrais na fase gestacional. Palavras chave: Fenilcetonúrias, Fenilalanina, Triagem neonatal ABSTRACT: Abstract Phenylketonuria is one of the main causes of intellectual disability, and it has effective treatment, if the diagnosis and treatment is performed early and a lifelong follow-up. The objective of this study is to determine the prevalence of newborns with phenylketonuria identified by newborn screening.  Methods: A cross-sectional study was carried out in which a data collection on newborn screening for phenylketonuria disease was carried out at the Newborn Screening Reference Service from January 1, 2010 to December 31, 2015.  Results: It was found in a 5-year period, an approximate prevalence of phenylketonuria of 1: 14,700 and permanent hyperphenylalaninemia is 1: 54,500 newborns. By means of the obtained results, it is possible to demonstrate the relevance of the recollects and the follow-up in the first year of life and of altered samples, as well as the severity of the female population with phenylketonuria and permanent hyperphenylalaninemia, emphasizing the increase of possible brain damages in the gestational phase. Conclusion: The prevalence of phenylketonuria and permanent hyperphenylalaninemia is high. Recollect and follow-up in the first year of life of the altered samples is extremely important, especially for the female population with phenylketonuria and permanent hyperphenylalaninemia, emphasizing the increase of possible brain damage in the gestational phase.  Keywords: Phenylketonurias. Phenylalanine, Newborn screening    

scholarly journals ESSENTIAL HYPERTENSION

2015 ◽  
Vol 22 (12) ◽  
pp. 1555-1559
Author(s):  
Mashooq Ali Dasti ◽  
Syed Fasih Ahmed Hashmi ◽  
Nisar Ahmed Shah ◽  
Syed Saad Hussain ◽  
Munaza Gohar ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Uric Acid ◽  
Essential Hypertension ◽  
Uric Acid Level ◽  
Acid Level ◽  
University Hospital ◽  
Male Population ◽  
Cross Sectional ◽  
Female Population ◽  
The Mean

Objectives: To determine the frequency of hyperuricemia in patients withessential hypertension. Study Design: Cross sectional descriptive. Period: Six months study.Setting: Liaquat University Hospital Hyderabad. Patients and Methods: All the patients withessential hypertension visited at cardiac OPD / admitted in the ward were further evaluated forserum uric acid level. The data was analyzed in SPSS 16 and the frequency and percentage wascalculated. Results: During six months study period, total one hundred and eighty (180) patientswith essential hypertension were recruited and study for uric acid level. The mean age ±SDfor overall population was 52.84±8.72 whereas it was 55.83±7.93 and 50.75±8.95 in male andfemale population respectively. The mean ± SD of systolic and diastolic blood pressure (mmHg)in overall population was 160.50 ± 12.74 and 100.70±5.95 respectively. The mean ±SD serumuric acid level in overall population was 13.74±4.83 while it was 11.74±6.44 and 14.43±4.31 inmale and female population respectively). The male population was predominant in relation toage (p=0.02), the hyperuricemia was identified in 117/180 (65%) patients and it is statisticallysignificant in context to age (p<0.01) and gender (p<0.05) whereas mean ±SD of systolic anddiastolic blood pressure was also significant in relation to hyperuricemia. Conclusion: There isa relationship between hyperuricemia and hypertension and shown that the serum uric acid levelwas significantly increased in patients with essential hypertension.

Sign in / Sign up

Export Citation Format

Share Document